Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.
Medscape Medical News
Over Half of Targetable NSCLC Patients Miss Out on Correct Tx
